Hard Gelatin Capsule Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

The capsule manufacturing project requires a layered approvals architecture spanning central and state regulatory bodies, with CDSCO manufacturing licence serving as the primary regulatory touchpoint for GMP-compliant production.

• CDSCO Manufacturing Licence under Drugs and Cosmetics Act 1940 and Rules 1945, Schedule M compliance mandatory for sterile and non-sterile oral solid dosage forms; Form 25/28 for allopathic formulations
• State Drug Licence from the concerned State Drug Controller for the manufacturing premises, with site inspection per Schedule M requirements
• BIS Certification under IS 1629:2018 for hard gelatin capsules covering dimensions, dissolution, and moisture content specifications
• Pollution Control Board Consent under Water Act 1974 and Air Act 1981, with EIA Notification 2006 applicability for projects with land acquisition exceeding 50 acres or production capacity above 10 million units per annum
• GST Registration on the GSTN portal with composition scheme eligibility for turnover below ₹75 lakh, and IEC code for any export-oriented production
• Factory Licence under Factories Act 1948 through the respective state Directorate of Industrial Safety and Health, with annual renewal and compliance reporting
• MSME Udyam Registration for MSMEs accessing priority sector lending and the CGTMSE credit guarantee cover, with collateral-free loans up to ₹5 crore
• EPF and ESI Registration for establishments employing 10 or more workers, with provident fund deductions and employee state insurance compliance

KAMRIT's engagement encompasses the full regulatory filings including CDSCO applications, SPCe+ incorporations, and pollution control consents, managed through single-window portals with state-specific timelines ranging from 45 to 120 working days for fresh licences.

The capsule sub-sector within oral solid-dosage forms is distinct from tablet and syrup segments due to its capital-intensive tooling requirements and the specialized gelatin supply chain. The sub-segment serves pharmaceutical companies (contract and branded generic), nutraceutical manufacturers, and ayurvedic producers. Within hard gelatin capsules, the vegetarian HPMC capsule segment is growing at 18-20% annually, outpacing the 13-14% growth in animal-sourced gelatin capsules, driven by ayurvedic and wellness sector demand.

Empty capsule manufacturers operate on thin margins (8-12% EBITDA) with high asset turnover, while filled capsule formulations command 18-25% EBITDA margins. The USFDA-cleared export segment commands 25-30% premium over domestic formulations, creating a clear pathway for GMP-certified plants to access higher-margin export markets. Contract manufacturing in the capsule sub-segment is particularly attractive given the capital intensity mismatch between capsule manufacturers and formulation companies seeking to outsource production.

Hospital pharmacy channels, growing at 12% annually, prefer capsule formulations for their dose accuracy and swallowability advantages over tablets for geriatric patients.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

Capsule manufacturing technology spans empty capsule production and filled capsule manufacturing as distinct operational streams. For empty capsule production, the equipment chain includes gelatin dissolution tanks, capsule pin moulding machines (from Macopac or Hattori), and automatic sorting and printing lines. For filled capsule production, the core equipment is the capsule filling machine, with Bosch TGs 1700 series, MG2 (Easymed) models, and Qualicaps lines representing the premium European and Japanese technology tier, while Chinese manufacturers like Jiche offer competitive pricing for smaller scale operations.

CapEx benchmarks for a 100 million capsules per annum line range from ₹6.0 crore for a semi-automatic Qualicaps or Jiche line to ₹35 crore for a fully automatic Bosch TGs installation with in-line metal detection and printing. Energy consumption in capsule filling averages 2.5-3.5 kWh per thousand capsules, with gelatin-based capsules requiring climate-controlled environments (18-22 degrees Celsius, 45-55% RH) to maintain dimensional consistency. Water consumption averages 8-12 kilolitres per day for a medium-scale plant.

Conversion cost for filled capsules in India ranges from ₹0.15 to ₹0.35 per capsule depending on fill complexity, compared to ₹0.30-0.60 per capsule in China for comparable specifications.

For a ₹20 crore mid-scale capsule plant project, KAMRIT recommends a debt-equity ratio of 70:30 leveraging the PLI scheme for bulk drugs and medical devices where capsule inputs qualify. SIDBI offers specific MSME healthcare financing schemes with a 75 basis points concession on base rate for GMP-certified plants, making SIDBI term loans at 8.5-9.0% the primary debt source. For working capital, HDFC and Axis Bank provide inventory finance against gelatin stock and receivables discounting against confirmed pharmaceutical offtake orders. SBI Healthcare finance desk has dedicated appraisal teams for pharma projects with turnaround time under 45 days. PMEGP loans up to ₹50 lakh are available for micro-enterprises through KVIC channels, while CGTMSE covers collateral-free portions up to ₹5 crore for units registered under MSME Udyam. State schemes in Gujarat, Maharashtra, and Himachal Pradesh offer 10-15% capital subsidies for pharma manufacturing units located in designated industrial areas. Working capital cycle for capsule plants typically runs 45-60 days given the 30-day gelatin procurement cycle and 45-day receivables from pharmaceutical formulation companies.

Raw material price volatility represents the primary risk, with pharmaceutical-grade gelatin prices fluctuating 15-25% annually based on bovine hide availability and global protein demand; mitigation involves forward contracts with suppliers like Tessenderlo Chemie or Karl Lammers and maintaining 45-60 days of inventory buffer. USFDA import alert risk remains material for any export-oriented plant, requiring continuous documentation of batch traceability and deviation reporting; the mitigation structure includes a dedicated quality assurance team, annual mock audits per ICH Q10 guidelines, and engagement with regulatory consultants for pre-approval inspections. Demand concentration risk exists where mid-scale plants serving single pharmaceutical formulation companies may face volume concentration issues; mitigation involves maintaining a diversified customer base across 8-12 pharmaceutical companies and securing multi-year supply agreements with take-or-pay provisions for a minimum of 60% capacity utilisation.

Sensitivity analysis across production volumes indicates that at 55% utilisation the project IRR falls to 14-16% from the base case of 22-25%, while feedstock price increases of 20% compress EBITDA margins by 4-5 percentage points.